Loading, please wait ...


News Analytics

be282912d1956e25f9e5e9ca4e7e0b2a4abb56ea 507x337 jpg?fit=crop&auto=format.
At the time of that testimony, there were 136 patents for Humira, and Gonzalez explained that the company had generously allowed competitors to bring biosimilar versions of adalimumab to market “literally 10 years before the last patent expires in that portfolio.” The first adalimumab biosimilars will enter the US market in 2023, according to patent settlements between AbbVie and the biosimilar developers.
Google

Subject Matter

  • Business, economics, society 70.00%
    • Society and people 59.18%
    • Companies, industries, organizations 40.82%
  • Healthcare 30.00%
    • Hospitals, doctors and medical care 100.00%

Emotional Reaction

Sentiment

Positive

Neutral

Negative

Definitions